Coherus BioSciences, Inc. (NASDAQ:CHRS) CFO Mcdavid Stilwell bought 3,700 shares of Coherus BioSciences stock in a transaction on Wednesday, June 9th. The stock was acquired at an average cost of $13.42 per share, with a total value of $49,654.00. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Shares of Coherus BioSciences stock opened at $14.02 on Friday. The business has a 50-day simple moving average of $14.04. The stock has a market cap of $1.06 billion, a P/E ratio of -11.49 and a beta of 1.08. The company has a debt-to-equity ratio of 2.33, a quick ratio of 2.20 and a current ratio of 2.40. Coherus BioSciences, Inc. has a 1 year low of $12.90 and a 1 year high of $22.22.
Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings results on Thursday, May 6th. The biotechnology company reported ($2.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.09 by ($2.46). The firm had revenue of $83.03 million for the quarter, compared to analysts’ expectations of $97.87 million. Coherus BioSciences had a negative return on equity of 34.76% and a negative net margin of 17.23%. Research analysts forecast that Coherus BioSciences, Inc. will post -2.63 earnings per share for the current year.
CHRS has been the subject of several research reports. Maxim Group initiated coverage on Coherus BioSciences in a research note on Friday, May 7th. They set a “buy” rating and a $22.00 price target for the company. Barclays decreased their target price on Coherus BioSciences from $28.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, May 17th. HC Wainwright decreased their price target on Coherus BioSciences from $29.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, May 13th. TheStreet lowered Coherus BioSciences from a “c” rating to a “d-” rating in a research report on Monday, May 17th. Finally, Citigroup lowered their price objective on Coherus BioSciences from $30.00 to $27.00 in a research note on Thursday, February 25th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $24.00.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its product candidate pipeline includes biosimilars of Humira, Avastin, and Lucentis.
Featured Article: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.